The insulin-like growth factor-I receptor (IGF-IR) mediates the growth and differentiation effects of the IGFs. Cancer cells overexpress IGF-IRs and this may impart to the cancer cells a growth potential. Recombinant human IGF-I (rhIGF-I)was administered, at varying doses, to nude mice that develop fibrosarcomas following injection of NIH-3T3 cells overexpressing IGF-I receptors. The administration of rhIGF-I at higher doses resulted in a shortened latency period, i.e., tumors appeared earlier than in vehicle-treated animals, and once the tumors appeared, they grew faster in the mice receiving the greater doses of rhIGF-I. The effect was also dependent on the level of IGF-IR expression, namely, the higher expression level of the receptor, the more responsive were the tumors. In studying the signaling pathways involved in IGF-I receptor- related tumor growth, we have identified a family of adapter proteins that may be involved in this process. CrkII and CrkL are SH2-SH3 domain-containing proteins. IGF-I receptor activation induces high-level tyrosine phosphorylation of both proteins and they both interact with insulin receptor substrate (IRS) molecules, whereas only CrkII interacts with the IGF-I receptor. Furthermore, the interaction of CrkII and CrkL with IRS-4 is different; Crk II interacts primarily via its SH2 domain, whereas CrkL requires both the SH2 domain and the N- terminal SH3 domain. This interaction with IRS-4 is tyrosine phosphorylation-dependent and deletion mutants demonstrated a central group of four residues (#700, 717, 743, 779) in IRS-4 that are involved in this interaction. When a fusion protein involving green fluorescent protein (GFP) and Crk proteins were expressed in cells in culture, followed by IGF-IR activation, GFP-CrkII was concentrated in the focal adhesion sites, whereas GFPCrkL remained diffusely expressed throughout the cell. Thus, CrkII may play a role in the differentiated function following IGF-IR activation, whereas CrkL mediates a more oncogenic response to IGF-IR activation. Their differential interaction with the IGF-IR and IRS molecules, and presumably downstream signaling molecules may be one of the mechanisms whereby they mediate these different functions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK047001-16
Application #
6105558
Study Section
Special Emphasis Panel (DB)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code